Innovative Drugs At Center Of China’s 2024 Regulatory Efforts

Review Process, Pricing And Insurance On Agenda

 
• By Xu Hu
  
2024 and 2025 arrows
China's regulations for the biopharma industry centered around innovative drugs in 2024; in 2025, it may be a continuation of that. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from China

More from Review Pathways